However, among 173 patients with stage III and IV HNSCC, the DFS rate in patients with TET3 methylation was 41.8%, as compared with 51.9% in the TET3 unmethylated group (log-rank test, P = 0.302) (Figure 4F). Here, TET3 is linked to head and neck squamous cell carcinoma.